|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowance for credit losses of $2,436 and $2,214 at 2023 and 2022, respectively | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Income taxes receivable | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| TOTAL CURRENT ASSETS | ||||||||||||||||||||
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $315,027 and $314,737 at 2023 and 2022, respectively | ||||||||||||||||||||
| RIGHT OF USE ASSETS | ||||||||||||||||||||
| INTANGIBLES AND GOODWILL | ||||||||||||||||||||
| INTANGIBLES, net of accumulated amortization and impairment of $17,650 and $17,475 at 2023 and 2022, respectively | ||||||||||||||||||||
| GOODWILL | ||||||||||||||||||||
| Total iNTANGIBLES AND GOODWILL | ||||||||||||||||||||
| DEFERRED TAX ASSETS, net | ||||||||||||||||||||
| OTHER ASSETS | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Current maturities of long-term debt | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued payroll and related costs | ||||||||||||||||||||
| Taxes other than payroll and income | ||||||||||||||||||||
| Unearned revenues | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| TOTAL CURRENT LIABILITIES | ||||||||||||||||||||
| LONG-TERM DEBT, net | ||||||||||||||||||||
| CONTRACT LIABILITIES | ||||||||||||||||||||
| LONG-TERM OPERATING LEASE LIABILITIES | ||||||||||||||||||||
| DEFERRED COMPENSATION | ||||||||||||||||||||
| DEFERRED TAX LIABILITIES, net | ||||||||||||||||||||
| OTHER LONG-TERM LIABILITIES | ||||||||||||||||||||
| EQUITY: | ||||||||||||||||||||
| Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding | ||||||||||||||||||||
| Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,701,102 issued and 46,634,027 outstanding at 2023 and 46,699,102 issued and 46,631,934 outstanding at 2022 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Treasury shares (at cost), 67,075 at 2023 and 67,168 at 2022 | ||||||||||||||||||||
| Total Core Laboratories N.V. shareholders' equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| TOTAL EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND EQUITY | ||||||||||||||||||||
Loading...
